NASDAQ · PALI
Palisade Bio, Inc.
$1.19$0.00 (0.0%)
Palisade Bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 58.39% below the high.
Loading market information…
NASDAQ · CRIS · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Curis, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.28% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Curis, Inc.’s next earnings report is currently expected on Nov 5, 2026, with estimated earnings per share of -$2.29. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Curis, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company’s pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small-molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreements with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed three programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:41 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 |
|---|
| May 6, 2025 |
| -$25.00-9.65% vs estimate |
| $2.38M-10.23% vs estimate |
| Q4 2024 | Mar 31, 2025 | -$25.00+8.09% vs estimate | $3.35M+51.34% vs estimate |
|---|
| Q3 2024 | Nov 14, 2024 | -$34.00+7.1% vs estimate | $2.93M+29.26% vs estimate |
|---|
THE ANALYST VIEW
18 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1.19$0.00 (0.0%)
Palisade Bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 58.39% below the high.
$0.77-$0.03 (-3.15%)
Leap Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 78.5% below the high.
$3.31-$0.19 (-5.43%)
BriaCell Therapeutics Corp.’s quoted price sits in the lower half of its reported 52-week range, 75.35% below the high.
$6.75-$0.44 (-6.12%)
Athira Pharma, Inc.’s quoted price sits in the upper half of its reported 52-week range, 19.26% below the high.
$0.56+$0.02 (+4.07%)
Citius Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 65.45% below the high.
$2.85-$0.15 (-5.0%)
Entero Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 51.2% below the high.
$0.80-$0.02 (-2.22%)
Hoth Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 67.29% below the high.
$2.31-$0.17 (-6.85%)
SeaStar Medical Holding Corporation’s quoted price sits in the lower half of its reported 52-week range, 61.5% below the high.
